YESAFILI Solution for injection Ref.[51275] Active ingredients: Aflibercept

Source: European Medicines Agency (EU)  Revision Year: 2023  Publisher: Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

Product name and form

Yesafili 40 mg/mL solution for injection in a vial.

Pharmaceutical Form

Solution for injection (injection).

Clear, colourless to pale yellow and iso-osmotic solution.

Qualitative and quantitative composition

1 mL solution for injection contains 40 mg aflibercept*.

One vial contains an extractable volume of at least 0.1 mL, equivalent to at least 4 mg aflibercept. This provides a usable amount to deliver a single dose of 0.05 mL containing 2 mg aflibercept.

* Fusion protein consisting of portions of human VEGF (vascular endothelial growth factor) receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Aflibercept

Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.

List of Excipients

Histidine
Histidine hydrochloride monohydrate
Polysorbate 20 (E432)
Trehalose dihydrate
Water for injections

Pack sizes and marketing

Solution in a vial (type I glass) with a stopper (chlorobutyl rubber). Each vial contains an extractable volume of at least 0.1 mL.

Yesafili is available in 2 different packs:

One pack containing 1 vial and a 5-micron sterile filter needle (18 G × 1½-inch).

One pack containing 1 vial, a 5-micron sterile filter needle (18 G × 1½-inch), a 1 mL Luer-lock syringe and an injection needle (30 G × ½-inch).

Not all pack sizes may be marketed.

Marketing authorization holder

Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland

Marketing authorization dates and numbers

EU/1/23/1751/001
EU/1/23/1751/002

Drugs

Drug Countries
YESAFILI Austria, Estonia, Croatia, Ireland, Lithuania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.